Ebola mAb114 vial

FREDERICK, Md. -- Just 48 hours after an Ebola clinical trial in the Democratic Republic of Congo (DRC) was stopped early because two therapies appeared to significantly reduce patients’ fatality rates, two Frederick National Laboratory staff members boarded a plane to help with the next step.

Meanwhile, the national laboratory’s Vaccine Clinical Materials Program (VCMP) sent a shipment of mAb114, one of the therapies, to the DRC.

Purdue University. Image by David Mark from Pixabay.

FREDERICK, Md. – Frederick National Laboratory for Cancer Research has launched a partnership with Purdue University that aims to enhance and accelerate research initiatives, technological innovation, and workforce development in the biomedical sciences.

FNL Chief Science Officer Leonard Freedman, Ph.D. gave the keynote presentation at the 15th anniversary of the Instituto Nacional de Medicina Genómica in Mexico City. Photo courtesy of INMEGEN.

MEXICO CITY -- An engagement between the Frederick National Laboratory for Cancer Research and the National Cancer Institute of Mexico (INCan) kicked off in July with a presentation about the FNL to a gathering of Mexican cancer researchers in Mexico City. 

FNL Chief Science Officer Leonard Freedman, Ph.D. highlighted some of the national laboratory’s key initiatives in a talk at a conference marking the 15thanniversary of the Instituto Nacional de Medicina Genómica (INMEGEN), one of Mexico’s 12 national institutes under the Secretariat of Health.

This animation created with cryo-EM structures depicts the pathway of the CRISPR Cas9 enzyme as it cuts DNA for gene editing. Animation courtesy of Xing Zhu, Miljan Simonovic and Sriram Subramaniam.

FREDERICK, Md. -- CRISPR is one of the most widely used technologies in the nascent quest to edit the human genome, and the precision “instrument” that makes it so effective is Cas9, a programmable enzyme harnessed from bacterial cells that cuts DNA strands at specific targets and replaces one gene with another.

David Pan watches the Vaccine, Immunity, and Cancer Program’s robot that performs automated testing for anti-HPV antibodies.

FREDERICK, Md. -- Ligia Pinto, Ph.D., sees science as a way to change lives and help people in need—and that is precisely what a study recently co-authored by her team at the Frederick National Laboratory for Cancer Research and collaborators at the H. Lee Moffitt Cancer Center and Research Institute and Weill Cornell Medicine holds promise to do.

HIV image. Photo courtesy National Institute of Allergy and Infectious Diseases.

FREDERICK, Md. -- Recent scientific papers co-authored by researchers at the Frederick National Laboratory for Cancer Research present novel discoveries about HIV and one similar infection from three fields of inquiry about the virus, all with the potential to further discoveries leading to prevention or treatment of HIV infection.

Ethan Dmitrovsky with Hood College symposium attendees.

FREDERICK, Md. – Leading experts in the imaging science and cancer biology field convened at Hood College June 21-23 for an in-depth look at the potential of new imaging technologies to transform their work. The Imaging Science and Cancer Biology Symposium, sponsored by Hood College and Leidos Biomedical Research, Inc. featured presentations exploring advances in understanding the mechanisms altering cancer cell signaling—as recently enabled by advanced imaging tools.

Tumor tissue will undergo testing for changes in more than 160 genes. If a patient's tumor has a genetic change that matches one targeted by a drug used in the trial, the patient may be eligible to join the treatment arm targeting that genetic change.

FREDERICK, Md. -- The National Cancer Institute–Children’s Oncology Group trial known as Pediatric MATCH (Molecular Analysis for Therapy Choice) trial launched in 2017, with significant operations and technical support from the Frederick National Laboratory for Cancer Research. Focusing on patients aged 1–21, Pediatric MATCH seeks to determine whether precision medicines that are designed to treat specific cancers with certain mutations can also treat other cancers with the same mutations.

NHP Models- Medicine, Simian Immunodeficiency Virus (SIV), Simian/Human Immunodeficiency Virus (SHIV), FNL SHIVs, FNL Barcoded SIV, Analysis, Study Design

FREDERICK, Md. -- Scientists at the Frederick National Laboratory for Cancer Research, the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center, and a team of collaborators have filled a gap in HIV research by developing 38 new simian/human immunodeficiency viruses (SHIVs) for prevention and treatment studies. The viruses are available to the scientific community through the national laboratory’s AIDS and Cancer Virus Program (ACVP).

Stock image of blood in a test tube

FREDERICK, Md. – Tissue biopsies are currently the norm for detecting and obtaining information about cancer. But this type of biopsy can be invasive, and not every patient can have one performed due to the location of their tumor or other health factors.